BiotechTube

Ganciclovir

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cytomegalovirus Infections

Conditions

Cytomegalovirus Infections, HIV Infections

Trial Timeline

— → —

NCT ID
NCT00002024

About Ganciclovir

Ganciclovir is a pre-clinical stage product being developed by Roche for Cytomegalovirus Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT00002024. Target conditions include Cytomegalovirus Infections, HIV Infections.

What happened to similar drugs?

6 of 20 similar drugs in Cytomegalovirus Infections were approved

Approved (6) Terminated (3) Active (11)
❌mRNA-1647ModernaPhase 3
🔄ASP0113 + PlaceboAstellas PharmaPhase 3
🔄Letermovir tablet + Letermovir IVMerckPhase 3
✅LetermovirMerckApproved
🔄Letermovir + PlaceboMerckPhase 3
🔄LetermovirMerckPhase 3
🔄LetermovirMerckPhase 3

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (14)

NCT IDPhaseStatus
NCT00000668Phase 1Completed
NCT00002095Pre-clinicalCompleted
NCT00002015Pre-clinicalCompleted
NCT00001034Phase 2Completed
NCT00002024Pre-clinicalCompleted
NCT00002135Pre-clinicalCompleted
NCT00002025Pre-clinicalCompleted
NCT00002330Pre-clinicalCompleted
NCT00002251Pre-clinicalCompleted
NCT00002273Pre-clinicalCompleted
NCT00002247Pre-clinicalCompleted
NCT00002134Pre-clinicalCompleted
NCT00002257Pre-clinicalCompleted
NCT00000688Phase 3Completed

Competing Products

20 competing products in Cytomegalovirus Infections

See all competitors
ProductCompanyStageHype Score
mRNA-1273ModernaPhase 1
0
mRNA-1647ModernaPhase 2
0
mRNA-1647ModernaPhase 2
0
mRNA-1647ModernaPhase 2
0
mRNA-1647ModernaPhase 2
0
mRNA-1647ModernaPhase 1
0
mRNA-1647ModernaPhase 2
0
mRNA-1647ModernaPhase 1
0
mRNA-1647ModernaPhase 3
0
ASP0113 + PlaceboAstellas PharmaPhase 2
35
ASP0113 + PlaceboAstellas PharmaPhase 3
40
Letermovir oral granules + Letermovir tablet + Letermovir intravenousMerckPhase 2
35
Letermovir 240 mg Oral TabletMerckPhase 2
42
Letermovir tablet + Letermovir IVMerckPhase 3
40
LetermovirMerckPhase 1
36
LetermovirMerckApproved
43
Letermovir 480 MG [Prevymis]MerckPhase 2
42
V160 Low Dose IM + V160 Medium Dose IM + V160 High Dose IM + V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM + V160 High Dose plus MAPA 225 µg /dose IM + V160 Maximum Dose IM + V160 Medium Dose IDMerckPhase 1
29
GanciclovirMerckPre-clinical
26
Letermovir + PlaceboMerckPhase 3
40